Why Biotech ETFs Are Beating the Market

Biotech stocks have been outperforming the broader market over the past three months, driven by optimism regarding potential rate cuts. The Fed is expected to start cutting rates later this month, and traders anticipate a total of 100 basis points in rate cuts by the end of the year.

Many smaller biotech companies are unprofitable and rely on debt to fund their research. A lower cost of capital generally results in better performance for the sector.

Additionally, big pharma’s willingness to pursue deals increases with declining interest rates. With record levels of cash on their balance sheets, these pharmaceutical companies are looking to acquire small, innovative firms to boost their pipelines.

At the same time, the sector is experiencing unprecedented innovation in multiple areas, including treatments for obesity and cancer, as well as advancements in gene editing.

The SPDR S&P Biotech ETF XBI, the most popular product in the space, tracks an equal-weighted index and is therefore tilted towards smaller companies.

The iShares Biotechnology ETF IBB tracks a market-cap-weighted index, with Gilead Sciences GILD and Regeneron Pharmaceuticals REGN as the top holdings.

The ALPS Medical Breakthroughs ETF SBIO focuses on innovative small- and mid-cap biotech companies.

To learn more, please watch the short video above.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research